Table 2.
Parameter estimates for doxorubicin and doxorubicinol pharmacokinetic model
| Parameter (unit) | Estimate (RSE) [Shrinkage] | Bootstrap median [95% CI] |
|---|---|---|
| CLdox (l h–1) | 54.2 (2%) | 54.1 [52.2, 55.8] |
| VC‐dox (l) | 16.9 (2%) | 16.8 [16.0, 17.5] |
| Q2‐dox (l h–1) | 66.1 (3%) | 66.3 [63.5, 69.5] |
| V2‐dox (l) | 1650 (3%) | 1648 [1547, 1741] |
| Q3‐dox (l h–1) | 23.4 (4%) | 23.3 [21.4, 25.1] |
| V3‐dox (l) | 61.8 (6%) | 61.6 [54.7, 69.6] |
| BSV | ||
| BSV‐CLdox (% CV) | 8.33 (33%)[19%] | 8.01 [2.51, 12.9] |
| BSV‐VC‐dox (% CV) | 10.5 (33%)[26%] | 10.5 [2.98, 16.7] |
| BSV‐Q2‐dox (% CV) | 15.4 (20%)[10%] | 14.8 [8.89, 21.5] |
| BSV‐V2‐dox (% CV) | 26.7 (18%)[11%] | 25.8 [13.4, 35.4] |
| IOV | ||
| IOV‐CLC‐dox (% CV) | 3.86 (29%)[42%] | 3.93 [1.67, 6.13] |
| RUV | ||
| RUV‐proportional‐dox (% CV) | 8.73 (9.8%) [13%] | 8.47 (6.88, 9.99) |
| RUV‐additive‐dox (SD) | 0.60 (41%) [13%] | 0.52 (0.034, 1.79) |
| CLdoxo'ol/fm (l h–1) | 106 (5%) | 105 [95–116] |
| VC‐doxo'ol/fm (l) | 1880 (9%) | 1876 [1582–2205] |
| BSV | ||
| BSV‐CLdoxo'ol/fm (% CV) | 18.5 (30%) [10%] | 17.8 [5–18] |
| BSV‐Vdoxo'ol /fm (% CV) | 37.3 (15%) [0%] | 35.7 [24.7–48.0] |
| IOV | ||
| IOV‐CLdoxo'ol/fm (% CV) | 11.9 (43%) [49%] | 11.4 [2.3–19.6] |
| IOV‐Vdoxo'ol/fm (% CV) | 9.39 (26%) [47%] | 8.72 [2.64–13.3] |
| RUV | ||
| RUV‐proportional‐doxo'ol (% CV) | 14.9 (12%) [12%] | 14.6 [11.4–18.4] |
BSV was calculated from and expressed as the CV%. Proportional RUV is expressed as CV%, and additive RUV as SD. RSE is expressed as CV% (RSE of BSV, IOV and RUV is expressed in term of SD). Shrinkage of BSV, IOV and RUV is presented in square brackets. CI, confidence interval; BSV, between‐subject variability; CV%, coefficient of variation; dox, doxorubicin; doxo'ol, doxorubicinol; IOV, interoccasion variability; RSE, relative standard error; RUV, random unexplained variability; SD, standard deviation.